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This research evaluated the physicochemical equivalence of some samples of Nifedipine 20 mg Retard 
Tablets available in Nigeria. Seven samples were randomly procured from various zones of the country 
and standard protocols applied to evaluate their tablet weight uniformity, dimensions, hardness, 
disintegration time, content of active Ingredient and in vitro drug release profile. Results showed that all 
the samples tested were chemically, but not physically equivalent. Although within each sample, 
compendial requirement for tablet weight uniformity was met, there were significant differences in the 
mean tablet weights, diameters and thickness of the samples studied (p < 0.05). Furthermore, tablet 
hardness and disintegration time varied much among the samples, but not within each sample. All the 
samples met the compendial requirement for content of active ingredient and released more than 80% 
of the drug within 4 h. It is therefore pertinent that manufacturers of this product be advised to 
formulate tablets that are equivalent in size, as different tablet sizes may impart negative psychological 
effects on clinicians and their patients when the need arises for switch over from one product to 
another, since the availability of particular products is never guaranteed at all times in Nigeria, a largely 
import dependent nation.    
 





In Nigeria, all the brands of Nifedipine 20 mg retard 
tablets available in the market, except one, are imported. 
As a result of the high cost of branded products, prescrip-
tion and use of generic drug products is advocated in 
order that essential drugs would be affordable to all that 
need them.  
However, unscrupulous importers, in order to ensure 
that their products compete commercially with other 
products, may sometimes compromise quality. As a 
result, healthcare professionals sometimes wonder whether 
those generics are equivalent to their original counter-
parts and whether patients are put at risk (Wiyada et al., 
2002). Nifedipine is a calcium channel blocker used in the 
management of various cardiovascular diseases (Neal, 
1995).  It belongs to the dihydropyridine class of calcium 
channel blockers and is chemically known as dimethyl-1, 




*Corresponding author. E-mail: ebypiaen@yahoo.com. Tel: 
+23408052742521. 
dicarboxylate. It is light sensitive and its photo-reaction 
products (nitrosophenylpyridine and nitrophenylpyridine 
derivatives) possess highly diminutized pharmacological 
activity. It is a yellow crystalline powder, with melting 
point range of 171 – 175oC (Al-Turk et al., 1989; Kennis 
et al., 2001; Martindale, 2002; USP/NF, 2002; BP, 2003).  
The effects of nifedipine are evident within 30-60 min of 
an oral dose (Kennis et al., 2001). The elimination half-
life for the immediate release formulation is 2-5h (CPS 
2002). Apart from the relatively short half-life of the 
immediate release formulation, they have other short 
comings such as flushing, dizziness, palpitation and 
reflex tachycardia. These have necessitated the formu-
lation of longer acting dosage forms and in some countries, 
the withdrawal of immediate release formulations from 
their markets (Brown et al., 1997; Minami et al., 2004; 
Emdex, 2006). In nifedipine retard, the rate of drug 
release is reduced by increasing particle size or forming 
insoluble crystals (MeRec, 2000).  
Other applications of nifedipine are in the management 
of exercise induced asthma (Barnes et al., 1981), primary 
Raynaud syndrome (Kennis et  al.,  2001),  prevention  of 




Table 1. Identities of the Nifedipine 20 mg retard samples used in the study. 
 
Code Country of Origin Shelf Life Status Batch No. NAFDAC No. 
A Nigeria Not Expired 2676T 04-3161 
B India Not Expired MOI  
C Israel Not Expired 06E86 04-4499 
D India Not Expired K51025 04-7584 
E Austria Not Expired P-909  
F Slovenia Not Expired 31951054 04-0766 




atherosclerosis (Hirata et al., 2000), amelioration of endo-
thelium  injury in patients with systemic sclerosis (Allanore 
et al., 2004) and enhancement of the activity of anti-








The samples (Table 1) studied were purchased from Lagos, Owerri, 
Onitsha, Ilorin, Suleja and Abuja. Nifedipine RS was purchased 
from Sigma-Aldrich Cheme GmbH, Germany. All other reagents 
were of analytical grade and water was double distilled. 
 
 
Tablet weight, dimensions and hardness measurements 
 
The weights of 20 tablets selected randomly from each sample 
were determined at room temperature using an electronic balance 
(Mettler Toledo B 154, Switzerland), while the dimensions (diameter 
and thickness) of 10 randomly selected tablets were measured 
using the Mitutoyo gauge (Model 10C-1012 EB Japan). The 
hardness values of another set of 20 tablets randomly selected 
from each sample were determined at room temperature using the 
Monsanto hardness tester (Monsanto Chemical Co. USA). The 





The disintegration times of the tablets were determined in distilled 
water at 37 ± 0.5°C using the disintegration tester (Manesty, Model: 
MK 4, UK). Thereafter, all other tests were carried out under 
subdued light.  
 
 
Calibration curve for Nifedipine RS 
 
Various concentrations of Nifedipine RS (1.5, 2.5, 5.0, 10.0, 15.0, 
20.0 and 25.0 µg/ml) were prepared in 0.1 M HCl. Their 
absorbances were read at 350 nm against 0.1 M HCl using a UV-
Visible spectrophotometer (UV-160 A Shimadzu Corporation 
Japan). The values of absorbance were plotted against the 
corresponding concentrations. Data used in plotting the curve were 
mean values of at least duplicate determinations. 
 
 
Content of active drug 
 
Five tablets were randomly selected from  each  sample  and  finely 
crushed in an agate mortar. An amount of powder equivalent to 20 mg 
of nifedipine was dissolved in 50 ml of methanol in a 100 ml volumetric 
flask and shaken vigorously for 15 min. Thereafter, the flask was made 
up to volume with more methanol. The solution was filtered through a 
Whatman No 1 filter paper and 2.5 ml of the clear filtrate was pipetted 
into a 50 ml volumetric flask and made up to volume with more 
methanol. The absorbance of the solution was measured at 350 nm 
using methanol as blank. The content of active drug was calculated 
based on the absorbance of 10.0 µg/ml of Nifedipine RS in methanol at 
the same wavelength. 
 
 
Dissolution rate    
 
The dissolution rate study was carried out using the USP XXIII 
(1995) basket method (Erweka dissolution tester, Type DT 80, 
Germany), operated at 50 rpm. The dissolution medium was 750 ml 0.1 
M HCl maintained at 37 ± 0.5ºC. Three tablets selected at random from 
each sample were used simultaneously for the study. A 5 ml volume of 
leaching fluid was withdrawn at various time intervals, filtered and 
appropriately diluted and its absorbance read at 350 nm against 0.1 
M HCl as blank. The dissolution medium was replenished with fresh 
5 ml aliquots at the same temperature after each sampling was 
done. The percentage of drug released was then calculated from 






The Fisher test (F-test) was employed to test whether there were 
significant differences between the means (µ) of the diameters, 
thicknesses, or weights of the samples studied. The post-hoc test: 
Fisher’s Least Significant Difference (FLSD) was carried out to 
locate the cause of the rejection of the null hypothesis (the means 
of the diameters, thicknesses, or weights of the tablets studied were 
equal) whenever it occurs. 
 
Fcalculated =  Treatment Mean Square / Error Mean Square  
 
FLSD = tcritical  s2 (1/ NA + 1/ NB) 
 
where NA and NB are the sizes of the two treatment groups, s2 is the 
pooled variance, estimated using the Error Mean Square term in 
the F-test and t critical is the critical t statistic associated with the 
experimental design (Jones, 2002).  The Fcalculated values were 
evaluated using Microsoft Excel 2007 ANOVA: Single Factor 
Analysis Tool Pack.                                   
 
 
RESULTS AND DISCUSSION 
 
All the Nifedipine 20 mg Retard tablets studied were 
within   their  shelf  lives  (Table 1).  Each  had  a  labeled 




Table 2. Tablet weights of the Nifedipine 20 mg retard samples used in the study (mg). 
 
A B C D E F G 
81.4 174.2 205.5 83.8 189.0 180.2 202.8 
82.0 145.8 203.7 83.0 195.1 180.5 205.0 
80.6 174.7 203.1 82.2 185.3 179.5 202.4 
83.8 168.5 207.5 87.6 194.9 178.6 200.6 
80.0 169.1 200.8 81.3 194.2 179.2 206.5 
80.4 170.4 204.1 86.0 192.8 177.9 203.0 
82.1 165.3 204.5 83.9 191.5 180.0 202.9 
81.1 178.8 205.2 83.4 188.0 180.2 203.8 
79.7 169.4 203.1 84.1 190.0 179.2 201.8 
82.1 180.9 205.0 86.7 193.7 178.1 202.7 
80.1 182.0 203.0 85.3 198.1 179.0 203.5 
81.6 174.2 207.8 80.7 198.1 177.9 204.8 
81.7 167.8 200.4 82.8 189.8 180.7 201.6 
79.8 193.6 204.7 85.0 195.4 178.5 203.2 
82.0 180.2 202.0 83.3 199.7 180.2 198.9 
82.0 182.1 201.9 81.3 197.2 179.5 201.6 
83.0 187.4 204.7 82.5 194.6 181.4 199.6 
81.7 167.7 206.3 80.6 189.3 176.9 203.8 
83.8 186.1 203.0 81.3 198.2 178.2 204.3 
81.3 180.5 206.2 85.2 182.4 177.5 203.7 
µ: 81.51 174.94 204.13 83.50 192.87 179.16 202.83 
s: 1.191 10.290 2.023 2.007 4.630 1.197 1.812 
 




Table 3. Some physicochemical characteristics of the Nifedipine 20 mg Retard samples studied. 
 
Tablet dimensions (mm) Code Tablet weight* 







A 81.51(1.191) 5.66(0.010) 3.10(0.018) 5.65(1.631) 7.91(1.197) 101.1 
B 174.94(10.290) 7.95(0.019) 3.70(0.079) 4.95(0.945) 2.17(0.621) 104.3 
C 204.13(2.023) 8.14(0.009) 4.07(0.020) 5.05(0.510) 1.08(0.132) 95.7 
D 83.50(2.007) 5.64(0.004) 3.14(0.047) 5.70(0.571) 17.39(2.355) 98.9 
E 192.87(4.630) 8.16(0.010) 3.79(0.066) 7.80(0.894) 7.06(0.822) 106.5 
F 179.16(1.197) 8.20(0.008) 4.11(0.030) 7.50(0.607) 38.79(5.398) 102.2 
G 202.83(1.812) 8.12(0.005) 3.80(0.042) >11.00(-) 47.41(4.107) 94.6 
 




strength of 20 mg nifedipine as a slow release 
formulation. Of the seven (7) samples studied, two (2), B 
and E, were not registered with the National Agency for 
Food and Drug Administration and Control (NAFDAC). 
Only one (1) sample, A, was formulated in Nigeria. 
Tables 2 and 3 show some of the physicochemical 
characteristics of the samples studied. The compendial 
requirement (BP, 2004) for tablet weight uniformity is met 
by all the samples in that not more than two of the 
individual weights from each sample deviated from the 
mean weight by more than 7.5% (Table 2). This compliance 
is important since the uniformity of dosage unit can be 
demonstrated by either weight variation or content 
uniformity study (USP/NF, 2003). These either reflect 
indirectly or measure directly the amount of drug sub-
stance in the tablet (Alderborn, 2002). The compliance 
within each sample notwithstanding, it is observable that 
the mean weight of the various samples varied widely 
and on application of ANOVA (Fisher’s-test) and its least 
significance difference (LSD) post hoc test, significant 
differences were revealed, with the mean tablet weights 
(µw) related as follows: µwA = µwD  µwC = µwG  µwB   µwE  
µwF (p < 0.05) (Tables 4c and 5). The test also revealed 
significant differences  among  the  samples  mean  tablet 




Table 4a. ANOVA results for tablet diameters. 
 
Source of Variation SS df MS F P-value F crit 
Between Groups 87.05378 6 14.50896 137453.3 1.1229E-127 2.246407983 
Within Groups 0.00665 63 0.000106    
Total 87.06043 69     
 





Table 4b. ANOVA results for tablet thicknesses.        
 
Source of Variation SS df MS F P-value F crit 
Between Groups 9.980789 6 1.663465 717.8456 5.34E-56 2.246408 
Within Groups 0.14599 63 0.002317    
Total 10.12678 69     
 





Table 4c. ANOVA results for tablet weights. 
 
Source of Variation SS df MS F P-value F crit 
Between Groups 349280.56 6 58213.43 2878.133 3.9E-138 2.167423 
Within Groups 2690.072 133 20.22611    
Total 351970.63 139     
 





diameters and thicknesses, with the post hoc identifying 
that: µdA= µdD  µdB  µdF  µdG  µdE = µdC = µdG, µtA  µtB  
µtC  µtD  µtF  µtE = µtG for mean tablet diameters and 
thicknesses respectively (p < 0.05) (Tables 4a, 4b, and 
5). These differences in the tablet sizes (that is, weight, 
diameter and thickness) may actually have some 
negative psychological effects on clinicians and their 
patients since they could raise doubts on the general 
equivalence of the different brands of nifedipine 20 mg 
retard tablets  available. Although the WHO Model 
Formulary (2002) advised that a patient be placed on a 
particular brand, probably due to pharmacokinetic and 
psychological reasons, in Nigeria where the availability of 
a particular brand for the patient concerned is never  
guaranteed at all times, it would be advisable that 
manufacturers of  this product formulate  tablets of 
equivalent sizes in order to assuage patients’ worry 
regarding the identity and efficacy of the different brands 
because of the wide differences in tablet sizes.   
Table 3 shows that the mean tablet hardness for the 
samples ranged from 4.95 to > 11.00 (Kg Sufficient tablet 
hardness is essential to ensure resistance to damage by 
handling, packaging and transportation. Tablet hardness 
of 4 kg is considered to be the minimum for a satisfactory 
tablet (Rudnic and Schwartz, 2000). The disintegration 
times of the samples varied widely too and cannot be 
predicted from the tablet hardness values. This is not 
unusual since different manufacturers adopt different 
formulation techniques to manipulate the disintegration 
and release properties of nifedipine retard tablets 
(MeRec, 2000). The content of active ingredient in all the 
samples is within the range required by the USP/NF 
(2003), that is, not less than 90.0% and not more than 
110.0% of the labeled content. Thus, all the samples 
studied are chemically equivalent. 
The in-vitro drug release profile (Figure 1) depicts that 
all the samples released more than 80% of their labeled 
contents within 4 h. The profiles were different however, 
in that some products released up to 50% of their 
contents within the first 1 h, while three of them (D, F and 
G) did not. These differences in the patterns of release 
must have been caused by the manufacturers’ choice of 
method of achieving reduction or delay in the rate of drug 
release (either increase in particle size or formation of 
insoluble crystals) (MeRec, 2000).  The need to release 
up to 50% within 1 h is important because there is benefit 
in attaining a good blood pressure control level within 1 h 
and then maintaining it for at least the next 2 h (Kennis et 
al., 2001). On the whole, all the Nifedipine Retard tablets 
tested performed creditably and may perform even better 
in vivo, in the presence of some biosolvents that may 
enhance their release profiles. 




Table 5. Fisher’s LSD test on the Samples at 0.05 level (two tailed) with critical values = 0.03d, 0.04t, 2.81w. 
 
Diameter Thickness Weight 
Compar. Diff. Signif. Compar. Diff. Signif. Compar. Diff. Signif. 
F – D 2.56 F D F – A 1.01 F  A C – A 122.62 C  A 
F – A 2.54 F  A F – D 0.97 F  D C – D 120.63 C   D 
F – B 0.25 F  B F – B 0.41 F  B C – B 29.19 C   B 
F – G 0.08 F  G F – E 0.32 F  E C – F 24.97 C   F 
F – C 0.06 F  C F – G 0.31 F  G C – E 11.26 C   E 
F – E 0.04 F  E F – C 0.04 F  C C – G 1.30 C = G 
E – D 2.52 E  D C – A 0.97 C  A G – A 121.32 G   A 
E – A 2.50 E  A C – D 0.93 C  D G – D 119.33 G   D 
E – B 0.21 E  B C – B 0.37 C  B G – B 27.89 G   B 
E – G 0.04 E  G C – E 0.28 C  E G – F 23.67 G   F 
E – C 0.02 E = C C – G 0.27 C  G G – E 9.96 G   E 
C – D 2.50 C  D G – A 0.70 G  A E – A 111.36 E   A 
C – A 2.48 C  A G – D 0.66 G  D E – D 109.37 E   D 
C – B 0.19 C  B G – B 0.10 G  B E – B 17.93 E   B 
C – G 0.02 C = G G – E 0.01 G = E E – F 13.71 E   F 
G – D 2.48 G  D E – A 0.69 E  A F – A 97.65 F   A 
G – A 2.46 G  A E – D 0.65 E  D F – D 95.66 F   D 
G – B 0.17 G  B E – B 0.09 E  B F – B 4.22 F   B 
B – D 2.31 B  D B – A 0.60 B  A B – A 93.43 B   A 
B – A 2.29 B  A B – D 0.56 B  D B – D 91.44 B   D 
A – D 0.02 A = D D – A 0.04 D  A D – A 1.99 D = A 
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All the samples of Nifedipine retard tablets studied perfor-
med well in vitro. However, manufacturers of nifedipine 
retard tablets and other sensitive drugs should be 
advised to formulate products that are identical in size 
and colour so that patients, especially non-literate ones 
would not doubt the similarity in effectiveness of the 
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